212 related articles for article (PubMed ID: 23808327)
1. Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor.
Shiao HY; Coumar MS; Chang CW; Ke YY; Chi YH; Chu CY; Sun HY; Chen CH; Lin WH; Fung KS; Kuo PC; Huang CT; Chang KY; Lu CT; Hsu JT; Chen CT; Jiaang WT; Chao YS; Hsieh HP
J Med Chem; 2013 Jul; 56(13):5247-60. PubMed ID: 23808327
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors.
Luo Y; Deng YQ; Wang J; Long ZJ; Tu ZC; Peng W; Zhang JQ; Liu Q; Lu G
Eur J Med Chem; 2014 May; 78():65-71. PubMed ID: 24681066
[TBL] [Abstract][Full Text] [Related]
3. SAR156497, an exquisitely selective inhibitor of aurora kinases.
Carry JC; Clerc F; Minoux H; Schio L; Mauger J; Nair A; Parmantier E; Le Moigne R; Delorme C; Nicolas JP; Krick A; Abécassis PY; Crocq-Stuerga V; Pouzieux S; Delarbre L; Maignan S; Bertrand T; Bjergarde K; Ma N; Lachaud S; Guizani H; Lebel R; Doerflinger G; Monget S; Perron S; Gasse F; Angouillant-Boniface O; Filoche-Rommé B; Murer M; Gontier S; Prévost C; Monteiro ML; Combeau C
J Med Chem; 2015 Jan; 58(1):362-75. PubMed ID: 25369539
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation.
Oguro Y; Miyamoto N; Okada K; Takagi T; Iwata H; Awazu Y; Miki H; Hori A; Kamiyama K; Imamura S
Bioorg Med Chem; 2010 Oct; 18(20):7260-73. PubMed ID: 20833055
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of aurora kinases inhibitors based on N-trisubstituted pyrimidine scaffold.
Long L; Luo Y; Hou ZJ; Ma HJ; Long ZJ; Tu ZC; Huang LJ; Liu Q; Lu G
Eur J Med Chem; 2018 Feb; 145():805-812. PubMed ID: 29358147
[TBL] [Abstract][Full Text] [Related]
7. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.
Tintori C; Fallacara AL; Radi M; Zamperini C; Dreassi E; Crespan E; Maga G; Schenone S; Musumeci F; Brullo C; Richters A; Gasparrini F; Angelucci A; Festuccia C; Delle Monache S; Rauh D; Botta M
J Med Chem; 2015 Jan; 58(1):347-61. PubMed ID: 25469771
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
[TBL] [Abstract][Full Text] [Related]
9. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.
Coumar MS; Chu CY; Lin CW; Shiao HY; Ho YL; Reddy R; Lin WH; Chen CH; Peng YH; Leou JS; Lien TW; Huang CT; Fang MY; Wu SH; Wu JS; Chittimalla SK; Song JS; Hsu JT; Wu SY; Liao CC; Chao YS; Hsieh HP
J Med Chem; 2010 Jul; 53(13):4980-8. PubMed ID: 20550212
[TBL] [Abstract][Full Text] [Related]
10. Ligand efficiency based approach for efficient virtual screening of compound libraries.
Ke YY; Coumar MS; Shiao HY; Wang WC; Chen CW; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Chang CM; Hsieh HP
Eur J Med Chem; 2014 Aug; 83():226-35. PubMed ID: 24960626
[TBL] [Abstract][Full Text] [Related]
11. Single step synthesis of new fused pyrimidine derivatives and their evaluation as potent Aurora-A kinase inhibitors.
Shaaban MR; Saleh TS; Mayhoub AS; Farag AM
Eur J Med Chem; 2011 Sep; 46(9):3690-5. PubMed ID: 21664013
[TBL] [Abstract][Full Text] [Related]
12. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
Arbitrario JP; Belmont BJ; Evanchik MJ; Flanagan WM; Fucini RV; Hansen SK; Harris SO; Hashash A; Hoch U; Hogan JN; Howlett AR; Jacobs JW; Lam JW; Ritchie SC; Romanowski MJ; Silverman JA; Stockett DE; Teague JN; Zimmerman KM; Taverna P
Cancer Chemother Pharmacol; 2010 Mar; 65(4):707-17. PubMed ID: 19649632
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties.
Xu S; Xu T; Zhang L; Zhang Z; Luo J; Liu Y; Lu X; Tu Z; Ren X; Ding K
J Med Chem; 2013 Nov; 56(21):8803-13. PubMed ID: 24124898
[TBL] [Abstract][Full Text] [Related]
14. Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach.
Chang Hsu Y; Ke YY; Shiao HY; Lee CC; Lin WH; Chen CH; Yen KJ; Hsu JT; Chang C; Hsieh HP
ChemMedChem; 2014 May; 9(5):953-61. PubMed ID: 24665000
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of BPR1K653 derivatives targeting the back pocket of Aurora kinases for selective isoform inhibition.
Ke YY; Chang CP; Lin WH; Tsai CH; Chiu IC; Wang WP; Wang PC; Chen PY; Lin WH; Chang CF; Kuo PC; Song JS; Shih C; Hsieh HP; Chi YH
Eur J Med Chem; 2018 May; 151():533-545. PubMed ID: 29656197
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a potent and selective aurora kinase inhibitor.
Oslob JD; Romanowski MJ; Allen DA; Baskaran S; Bui M; Elling RA; Flanagan WM; Fung AD; Hanan EJ; Harris S; Heumann SA; Hoch U; Jacobs JW; Lam J; Lawrence CE; McDowell RS; Nannini MA; Shen W; Silverman JA; Sopko MM; Tangonan BT; Teague J; Yoburn JC; Yu CH; Zhong M; Zimmerman KM; O'Brien T; Lew W
Bioorg Med Chem Lett; 2008 Sep; 18(17):4880-4. PubMed ID: 18678489
[TBL] [Abstract][Full Text] [Related]
17. Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.
Coumar MS; Tsai MT; Chu CY; Uang BJ; Lin WH; Chang CY; Chang TY; Leou JS; Teng CH; Wu JS; Fang MY; Chen CH; Hsu JT; Wu SY; Chao YS; Hsieh HP
ChemMedChem; 2010 Feb; 5(2):255-67. PubMed ID: 20039358
[TBL] [Abstract][Full Text] [Related]
18. A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.
Li J; Hu H; Lang Q; Zhang H; Huang Q; Wu Y; Yu L
Eur J Med Chem; 2013 Jul; 65():151-7. PubMed ID: 23707920
[TBL] [Abstract][Full Text] [Related]
19. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
[TBL] [Abstract][Full Text] [Related]
20. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
